Each advancement in cancer research brings renewed hope to millions battling this devastating disease.

Scientists at the UC Davis Comprehensive Cancer Center in Sacramento, California, have introduced a promising new approach to cancer treatment. Their findings, published in the journal Cell Death & Differentiation, highlight a breakthrough in targeting cancer cells.

Their research focuses on CD95 receptors, also known as Fas or “death receptors,” which trigger cancer cells to self-destruct. “Previous attempts to target this receptor have failed. However, now that we’ve identified this epitope (target), we may have a viable therapeutic strategy for addressing Fas in tumors,” explained Jogender Tushir-Singh, senior author of the study and associate professor in the Department of Medical Microbiology and Immunology.

These CD95 receptors are found on the surface of cells and, when activated, initiate molecular processes leading to cell destruction. While they are crucial for maintaining cellular balance, their full potential has remained largely unexplored until now.

One of the greatest challenges in cancer treatment is therapeutic resistance, where cancer cells adapt and become unresponsive to conventional therapies. Currently, standard treatments include surgery, chemotherapy, and radiotherapy. Additionally, immune-based therapies such as CAR (chimeric antigen receptor) T-cell therapy have been introduced, but their success has been limited to specific cancer types.

“Although CAR T-cell therapies have shown promise in treating blood cancers like leukemia, achieving long-term remission remains a major hurdle,” Tushir-Singh told Fox News.

The study suggests that this new discovery could significantly improve the effectiveness of CAR-T therapies, expanding their potential beyond leukemia to solid tumors.

By targeting the Fas epitope, researchers hope to prevent cancer cells from evading treatment by inducing programmed cell death. This approach could not only help overcome therapeutic resistance but also enhance the effectiveness of existing immunotherapies.

“The success of CAR-T therapy depends on off-target killing through Fas,” Tushir-Singh told Fox News Digital. He further emphasized the importance of screening cancer patients for Fas expression before undergoing CAR-T therapy to determine its potential effectiveness.